GIGABYTE launched its Future Landing theme at COMPUTEX 2026, marking a key stage in the large-scale implementation of AI.

GIGABYTE launched its “Future Landing” theme at COMPUTEX 2026, marking a key stage in the large-scale implementation of AI.

GIGABYTE Technology, a global leader in high-performance computing, showcased its most comprehensive end-to-end AI infrastructure product portfolio to date at COMPUTEX 2026 under the theme “Future Landing.” As AI officially…

Read MoreGIGABYTE launched its “Future Landing” theme at COMPUTEX 2026, marking a key stage in the large-scale implementation of AI.
Record Results Headlined by 287% Increase in Net Earnings and 257% Increase in Net Earnings per Share Driven by Continued Strength in Operations

Record Results Headlined by 287% Increase in Net Earnings and 257% Increase in Net Earnings per Share Driven by Continued Strength in Operations

Exchange Income Corporation reported record financial results for the first quarter ended March 31, 2026, driven by strong performance across its Aerospace & Aviation operations and continued momentum in strategic…

Read MoreRecord Results Headlined by 287% Increase in Net Earnings and 257% Increase in Net Earnings per Share Driven by Continued Strength in Operations
Drummond Scientific Company Acquires Accu-Glass, Cementing Its Position as Leading Glass Capillary Manufacturer

Drummond Scientific Company Acquires Accu-Glass, Cementing Its Position as Leading Glass Capillary Manufacturer

A leading manufacturer of medical technology, diagnostic, and sample collection devices, today announced the acquisition of Accu-Glass, LLC , a St. Louis-based manufacturer of high-precision glass capillaries used in medical and diagnostic…

Read MoreDrummond Scientific Company Acquires Accu-Glass, Cementing Its Position as Leading Glass Capillary Manufacturer
Cellares and ProTgen Join Forces to Streamline Production of ProT-096, a Novel T Cell Therapy Aimed at Restoring Immune Function

Cellares and ProTgen Join Forces to Streamline Production of ProT-096, a Novel T Cell Therapy Aimed at Restoring Immune Function

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the thymus and reconstitute the adaptive immune system, today announced…

Read MoreCellares and ProTgen Join Forces to Streamline Production of ProT-096, a Novel T Cell Therapy Aimed at Restoring Immune Function